SCHEMBL8028720

SCHEMBL8028720

COC(=O)c1cccc(N2C(=O)N(Cc3ccccc3Cc3ccccc3)C(C)(C)C2=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R8 Q9NYW2 3/20 0.51
GAA P10253 1/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HPGD P15428 3/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.39
AR P10275 1/20 0.39
PMM2 O15305 1/20 0.39
MPI P34949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12603217 0.90 SMN1; SMN2 (0.46) TAS2R8ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL8034638 0.90 TAS2R8 (0.47) TAS2R8HDAC1HDAC6RAB9AALDH1A1
SCHEMBL8026212 0.89 MCHR1 (0.44) TAS2R8HDAC1HDAC6RAB9AALDH1A1
SCHEMBL12603154 0.85 MCHR1 (0.50) TAS2R8MEN1KMT2AMCHR1
SCHEMBL1773797 0.85 MGLL (0.45) TAS2R8ARMCHR1
SCHEMBL8032947 0.85 AR (0.44) TAS2R8ARMCHR1
SCHEMBL1772969 0.85 AR (0.45) TAS2R8HDAC1HDAC6ARMCHR1
SCHEMBL8016018 0.84 TAS2R8 (0.46) TAS2R8GAAHDAC1HDAC6HPGD
SCHEMBL8030958 0.84 ELANE (0.46) TAS2R8AR
SCHEMBL12603129 0.83 MCHR1 (0.42) TAS2R8ARMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 US disclosed
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 US disclosed
WO-2009097997-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC TAS2R8 238/4885GAA 231/4885HDAC1 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.